CBD News Roundup: Lexaria to Study Anti-Seizure CBD Against Epidiolex

Here’s the latest CBD news:

• CBD drug developer Lexaria Bioscience has commenced a study that will compare their product to Epidiolex, an FDA-approved, CBD-based epilepsy medication.
• A new Gallup poll shows that more Americans than ever are supporting marijuana legalization. 
• The majority of CBD consumers are determining their own doses or not measuring at all, according to a new survey.

Lexaria to Compare Their Anti-Seizure CBD Formulation to Epidiolex

Canada-based pharmaceutical company Lexaria Bioscience Corp., developers of a CBD-based formulation (DehydraTECH TM), has announced the commencement of a study comparing the anti-seizure potential of their product against Epidiolex, the first and only FDA-approved anti-seizure drug made with CBD.

DehydraTECH has proven its efficacy for various conditions affecting the central nervous system and other issues (studies accessible through the above links), earning patents in 23 countries thus far. 

According to Lexaria’s press release, “Animal study EPIL-A21-1 has entered early-stage preparatory work and results are expected by Q3 2022.”

Respirologists and neurobiologists will conduct the study, which is fully funded by Lexaria, at an independent laboratory in the US.

Poll: Majority of Americans Support Marijuana Legalization

According to an 823-participant Gallup poll released yesterday (Nov 4), more than two-thirds of respondents (68%) indicated they are in support of marijuana legalization, which ties the 2020 poll at an all-time high.

Since the group has monitored public support of marijuana legalization (1969-ongoing), Gallup notes fairly linear growth, though there were “particularly sharp increases occurring in the 2000s and 2010s.”

Notably, 2013 was the year that supporters became the majority.

The greatest discrepancy between participant subgroups (divided by gender, race, age, education, political affiliation, and ideology) was between liberal (86%) and conservative (49%) supporters of legalization.

Survey: Few CBD Users Consult With Doctor for Dosage

A new survey from Leafreport released Wed, Nov 3 polled 721 active and former CBD users about their CBD dosage habits, revealing some striking trends in the process.

For example, an overwhelming 71% of CBD users “self-determine dosage without consulting a professional,” and 22% don’t determine dosage before taking products.

Just under half of respondents (48%) reported using the same dose consistently, and around a third of respondents (31%) reported taking CBD products every day.

As indicated by these results, the absence of the dosage and safety recommendations that comes with official regulation is causing consumers to address these issues themselves, or more troublingly, not address them at all.